ESMO Archives - Page 2 of 25

Innovative agents directed against RET, Trop-2, KRASG12C and HER2

The highly selective and potent RET kinase inhibitor selpercatinib has been implemented in the treatment of lung cancer harboring RET gene fusions. At the same time, the combination of platinum, pemetrexed and pembrolizumab is an established first-line standard of care for patients without EGFR or ALK alterations. The aim of the randomized, open-label, phase III LIBRETTO-431 study was to define the optimal first-line regimen for patients with RET-fusion–positive NSCLC.

ALK-targeted adjuvant treatment and perioperative immunotherapy

Approximately 30 % to 40 % of patients with non–small-cell lung cancer (NSCLC) are diagnosed with resectable disease. Depending on the stage, the risk of disease recurrence remains high in spite of treatment, which calls for more effective strategies. For patients with resectable ALK-positive NSCLC, the guidelines recommend adjuvant platinum-based chemotherapy, while immunotherapy is not recommended.

Preface – ESMO Lung Cancer 2023

It is a pleasure to present you the memo inOncology 2023. This time we report on the ESMO Congress held in Madrid, Spain, from 20th to 24th October 2023. It was an outstanding scientific and educational event with more than 33,000 participants from 155 countries.

Conventional chemotherapy combined with PD-1/PD-L1

Neoadjuvant chemotherapy (CT), which has been the standard-of-care for resectable NSCLC, resulted only in modest survival benefits of approximately 5 %. However, CT combined with neoadjuvant immunotherapy is a promising strategy in improving survival outcomes of patients with resectable NSCLC. Hence, several small single-arm phase II studies are ongoing in this setting, all including patients with stage III disease.

Emerging therapies in solid tumors

Interleukin-8 (IL-8), also known as chemokine (C-X-C motif) ligand 8, is a pro-inflammatory chemokine that exerts direct pro-tumorigenic effects primarily by recruiting immunosuppressive cells into the tumor microenvironment such as neutrophils and myeloid-derived suppressor cells. IL-8 has also been shown to promote cancer progression and resistance to therapy, by inducing angiogenesis, epithelial-mesenchymal transition (EMT), and cancer stem cell (CSC) self-renewal.

New strategies with PD-1/PD-L1 blockade in lung cancer

Small-cell lung cancer (SCLC) accounts for about 15 % of all diagnosed cases of lung cancer and is characterized by a high proliferative rate, an early development of widespread metastases and a poor prognosis. The five-year survival rate is less than 7 %. More than two-thirds of patients with this highly aggressive neuroendocrine tumor are diagnosed with advanced or extensive-stage disease (ES-SCLC).

Preface – ESMO IO 2022

The ESMO Immuno-Oncology Congress took place in Geneva, Switzerland, and virtually from 7th to 9th December 2022. In total, more than 2,000 participants from more than 100 countries attended one of the 31 sessions featuring over 249 presented abstracts, 6 late breaking abstracts, 6 proffered paper, 14 mini orals and 229 posters.

Oncology

Hematology

Solid Tumors

Hematologic Malignancies

Collaborations

Supporter

SPONSORS